A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry

Trial Profile

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms COSMiC
  • Sponsors Janssen Inc
  • Most Recent Events

    • 31 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Feb 2018 Results (n=264) data cut off as of September 2017 evaluating patient related outcomes in real world when treated with abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC) population presented at the 2018 Genitourinary Cancers Symposium.
    • 25 Oct 2017 Planned primary completion date changed from 15 Aug 2017 to 30 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top